Breast Cancer Update
By Dr. Neil Love
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Dr. Neil Love
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 32
Reviews: 0
Episodes: 108
Description
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.
| Episode | Date |
|---|---|
|
Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
|
Jul 13, 2026 |
|
For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress
|
Jul 10, 2026 |
|
Antibody-Drug Conjugates in the Management of Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
|
Jul 08, 2026 |
|
HR-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit
|
Jun 29, 2026 |
|
Metastatic Triple-Negative Breast Cancer — What Clinicians Want to Know
|
Jun 26, 2026 |
|
HER2-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit
|
Jun 23, 2026 |
|
Desmoid Tumors — Microlearning Activity 4 with Prof Bernd Kasper
|
Jun 22, 2026 |
|
Triple-Negative Breast Cancer — Fifth Annual National General Medical Oncology Summit
|
Jun 20, 2026 |
|
HR-Positive Metastatic Breast Cancer — A Discussion and Debate on First- and Second-Line Therapy
|
Jun 11, 2026 |
|
Desmoid Tumors — Microlearning Activity 3 with Prof Bernd Kasper
|
Jun 02, 2026 |
|
Oral SERDs for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
|
Apr 30, 2026 |
|
HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Optimizing Biomarker Assessment and Related Treatment Decision-Making
|
Apr 16, 2026 |
|
ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
|
Apr 14, 2026 |
|
Desmoid Tumors — Microlearning Activity 2 with Dr Ravin Ratan
|
Apr 07, 2026 |
|
Diabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN Pathway
|
Mar 30, 2026 |
|
Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Lajos Pusztai: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
|
Mar 18, 2026 |
|
Desmoid Tumors — Microlearning Activity 1 with Dr Ravin Ratan
|
Mar 16, 2026 |
|
Antibody-Drug Conjugates for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
|
Mar 02, 2026 |
|
Endocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series
|
Jan 27, 2026 |
|
HER2-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series
|
Jan 14, 2026 |
|
Antibody-Drug Conjugates for Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series
|
Jan 08, 2026 |
|
Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient Cases
|
Dec 23, 2025 |
|
Breast Cancer — Highlights from the 2025 ESMO Annual Meeting
|
Dec 08, 2025 |
|
Breast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
|
Dec 05, 2025 |
|
Breast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
|
Dec 02, 2025 |
|
Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
|
Nov 29, 2025 |
|
Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
|
Nov 26, 2025 |
|
HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
|
Nov 20, 2025 |
|
ER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDs
|
Nov 14, 2025 |
|
Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
|
Nov 10, 2025 |
|
ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders
|
Nov 05, 2025 |
|
Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
|
Oct 27, 2025 |
|
Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates
|
Oct 21, 2025 |
|
HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
|
Oct 14, 2025 |
|
Breast Cancer — An ASCO 2025 Review
|
Oct 07, 2025 |
|
Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
|
Sep 29, 2025 |
|
Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management
|
Sep 23, 2025 |
|
Metastatic Triple-Negative Breast Cancer — The Selection and Sequencing of Therapy
|
Sep 18, 2025 |
|
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management
|
Sep 16, 2025 |
|
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management
|
Sep 15, 2025 |
|
Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1
|
Sep 09, 2025 |
|
Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
|
Sep 01, 2025 |
|
Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management Approaches
|
Aug 26, 2025 |
|
Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
|
Aug 04, 2025 |
|
Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management
|
Jul 29, 2025 |
|
Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
|
Jul 04, 2025 |
|
IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies
|
Jun 23, 2025 |
|
For Oncology Nurses: Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS Congress
|
Jun 16, 2025 |
|
Breast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and Advances
|
Jun 04, 2025 |
|
5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
|
May 28, 2025 |
|
5-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
|
May 19, 2025 |
|
Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
|
May 06, 2025 |
|
For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress
|
Apr 26, 2025 |
|
Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy
|
Apr 25, 2025 |
|
HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit
|
Apr 21, 2025 |
|
HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology Summit
|
Apr 13, 2025 |
|
Breast Cancer — An Interview with Dr Adrienne G Waks on Recent Trial Updates
|
Apr 08, 2025 |
|
Neurofibromatosis Type 1 Plexiform Neurofibromas — An interview with Dr Christopher L Moertel
|
Mar 28, 2025 |
|
HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based Therapy
|
Mar 28, 2025 |
|
5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
|
Mar 22, 2025 |
|
Localized Breast Cancer — Examining the Current Use of Genetic Testing and Related Clinical Management
|
Mar 12, 2025 |
|
5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
|
Mar 04, 2025 |
|
HER2-Low and HER2-Ultralow Breast Cancer — A Roundtable Discussion on Current and Future Management Strategies
|
Feb 15, 2025 |
|
5-Minute Journal Club Issue 4 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
|
Feb 10, 2025 |
|
5-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
|
Jan 31, 2025 |
|
Metastatic Triple-Negative Breast Cancer — Oncology Q&A for Clinicians: Discussing Common Questions Posed by Patients
|
Jan 24, 2025 |
|
Oncology Q&A for Patients with Metastatic Triple-Negative Breast Cancer
|
Jan 17, 2025 |
|
Metastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3
|
Jan 10, 2025 |
|
The Role of Endocrine-Based Therapy in the Management of Breast Cancer — San Antonio 2024 symposium series proceedings Part 2
|
Jan 03, 2025 |
|
HER2-Low and HER2-Ultralow Breast Cancer — San Antonio 2024 symposium series proceedings Part 1
|
Dec 23, 2024 |
|
5-Minute Journal Club Issue 2 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
|
Dec 16, 2024 |
|
Exploring the Current Management Paradigm for Patients with Metastatic Triple-Negative Breast Cancer
|
Dec 05, 2024 |
|
5-Minute Journal Club Issue 1 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
|
Nov 26, 2024 |
|
Optimizing Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer Harboring PI3K/AKT/PTEN Pathway Abnormalities
|
Nov 19, 2024 |
|
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Breast Cancer
|
Nov 16, 2024 |
|
Improving Outcomes with First-Line Endocrine-Based Therapy for Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
|
Nov 01, 2024 |
|
Oncology Today with Dr Neil Love: Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
|
Oct 25, 2024 |
|
Practical Perspectives: Optimizing Diagnosis and Treatment for Patients with Desmoid Tumors
|
Oct 18, 2024 |
|
Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer
|
Sep 25, 2024 |
|
Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer
|
Sep 06, 2024 |
|
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
Aug 29, 2024 |
|
Oncology Today with Dr Neil Love: An interview with Professor Giuseppe Curigliano, MD, PhD — Management of Metastatic Breast Cancer
|
Aug 23, 2024 |
|
Oncology Today with Dr Neil Love: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metastatic Breast Cancer
|
Aug 16, 2024 |
|
Individualizing the Selection of First-Line Therapy for Patients with Hormone Receptor-Positive Metastatic Breast Cancer
|
Aug 07, 2024 |
|
Oncology Today with Dr Neil Love: Optimizing the Identification of HER2-Low Breast Cancer
|
Jul 31, 2024 |
|
What Clinicians Want to Know About the Management of Triple-Negative Breast Cancer
|
Jul 11, 2024 |
|
Striving for Consensus: Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer
|
Jun 13, 2024 |
|
Oncology Today with Dr Neil Love: Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast Cancer
|
May 21, 2024 |
|
Virtual Case Library: Metastatic Triple-Negative Breast Cancer
|
May 09, 2024 |
|
Oncology Today with Dr Neil Love: Overcoming Endocrine Resistance in ER-Positive Metastatic Breast Cancer
|
Mar 26, 2024 |
|
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer
|
Mar 15, 2024 |
|
Oncology Today with Dr Neil Love: Understanding the Current and Future Role of Oral SERDs (Selective Estrogen Receptor Degraders) in the Management of ER-Positive Metastatic Breast Cancer
|
Mar 11, 2024 |
|
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hormone Receptor-Positive Breast Cancer
|
Feb 01, 2024 |
|
Implications of Recent Data Sets for the Current and Future Management of Breast Cancer
|
Nov 30, 2023 |
|
Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer
|
Sep 29, 2023 |
|
Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part Series
|
Aug 30, 2023 |
|
Inside the Issue: Current and Future Management of ER-Positive Metastatic Breast Cancer After Disease Progression on a CDK4/6 Inhibitor
|
Aug 24, 2023 |
|
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Breast Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
|
Aug 09, 2023 |
|
Oncology Today with Dr Neil Love: Special Edition — Current and Future Management of Breast Cancer
|
Jul 21, 2023 |
|
Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2-Part Series
|
Jun 16, 2023 |
|
Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 3 of a 3-Part Series
|
Apr 27, 2023 |
|
Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 2 of a 3-Part Series
|
Mar 31, 2023 |
|
Recent Advances and Future Directions in Breast Cancer — With Dr Harold Burstein and Dr Virginia Kaklamani (Proceedings from a Symposium in Partnership with NCOA and SCOS)
|
Mar 17, 2023 |
|
Inside the Issue — Exploring the Current Role of Ovarian Suppression in the Management of Breast Cancer
|
Mar 10, 2023 |
|
Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 1 of a 3-Part Series
|
Feb 24, 2023 |
|
Oncology Today with Dr Neil Love: Special Edition — Management of ER-Positive Breast Cancer
|
Jan 31, 2023 |
|
Oncology Today with Dr Neil Love: HER2-Positive Metastatic Breast Cancer
|
Jan 26, 2023 |
|
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer
|
Jan 17, 2023 |